Author

I. De Castro Silva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

A. Bianchi· 3 shared J. Datta· 3 shared S. Mehra· 3 shared A. R. Dosch· 2 shared N. Merchant· 2 shared N. Nagathihalli· 2 shared P. J. Hosein· 2 shared P. Sharma· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Bianchi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Neutrophil-Mediated Stromal-Tumor IL-6/STAT-3 Signaling Underlies the Association between Neutrophil-to-Lymphocyte Ratio Dynamics and Chemotherapy Response in Localized Pancreatic Cancer: A Hybrid Clinical-Preclinical Study

I. de Castro Silva, P. Sharma, A. Bianchi, N. Deshpande, S. Mehra, J. England, P. J. Hosein, D. Kwon, N. Merchant, J. Datta

This study shows that neutrophil-to-lymphocyte ratio (NLR) dynamics predict chemotherapy response in pancreatic cancer and that targeting NLR improves chemosensitivity by modulating IL-6/STAT-3 signaling.

bioRxiv · May 4, 2022 · PreprintImmunology

Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with KRAS-TP53 Co-Alteration in Pancreatic Cancer

J. Datta, A. Bianchi, I. De Castro Silva, N. U. Deshpande, L. L. Cao, S. Mehra, S. Singh, C. Rafie, X. Sun, X. Chen, X. Dai, A. Colaprico, P. Sharma, A. R. Dosch, A. Pillai, , N. B. Merchant

bioRxiv · May 1, 2022Cancer Biology

Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancer

J. Datta, X. Dai, A. Bianchi, I. De Castro Silva, S. Mehra, V. T. Garrido, P. Lamichhane, S. Singh, Z. Zhou, A. R. Dosch, F. Messagio, Y. Ban, O. Umland, P. J. Hosein, N. Nagathihalli, N. Merchant

This paper shows that combining MEK and STAT3 inhibitors reprograms stromal inflammation and enhances immunotherapy response in pancreatic cancer.

bioRxiv · Mar 7, 2021 · PreprintCancer Biology